{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T02:06:59Z","timestamp":1792807619728,"version":"4.5.0"},"reference-count":165,"publisher":"MDPI AG","issue":"21","license":[{"start":{"date-parts":[[2024,10,29]],"date-time":"2024-10-29T00:00:00Z","timestamp":1730160000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJMS"],"abstract":"<jats:p>Thyroid eye disease is a complex inflammatory disorder of the orbit that has gained tremendous interest over the past years, and numerous scientific efforts have been deployed to elucidate its pathophysiology for novel drug development. Our manuscript will delve into the molecular dysregulations involved in the pathogenesis of thyroid eye disease that led to its clinical manifestations. Abnormalities within the apoptotic pathway, inflammatory cascade, and autoimmune regulatory systems will be covered. We will further discuss the challenges involved in its diagnosis and management and provide a summary of the current diagnostic tools (i.e., molecular biomarkers, diagnostic scores) from the perspective of clinicians. Finally, our comprehensive literature review will provide a thorough summary of most recent preclinical and clinical studies around the topic of thyroid eye disease, with an emphasis on the manuscripts published within the last five years. We believe our manuscript will bring novelty within the field by bridging the fundamental sciences with the clinical aspect of this disease. This review will be a great tool for clinicians in better understanding the pathogenesis of thyroid eye disease while providing an outlook on future perspectives (i.e., liquid biopsies, artificial intelligence).<\/jats:p>","DOI":"10.3390\/ijms252111628","type":"journal-article","created":{"date-parts":[[2024,10,29]],"date-time":"2024-10-29T10:45:35Z","timestamp":1730198735000},"page":"11628","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":42,"title":["A Comprehensive Review of Thyroid Eye Disease Pathogenesis: From Immune Dysregulations to Novel Diagnostic and Therapeutic Approaches"],"prefix":"10.3390","volume":"25","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2756-3973","authenticated-orcid":false,"given":"Merve","family":"Kulbay","sequence":"first","affiliation":[{"name":"Department of Ophthalmology & Visual Sciences, McGill University, Montreal, QC H4A 0A4, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1190-7129","authenticated-orcid":false,"given":"Stuti M.","family":"Tanya","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology & Visual Sciences, McGill University, Montreal, QC H4A 0A4, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicolas","family":"Tuli","sequence":"additional","affiliation":[{"name":"Faculty of Medicine and Health Sciences, McGill University, Montreal, QC H3G 2M1, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jade","family":"Dahoud","sequence":"additional","affiliation":[{"name":"Faculty of Medicine, University of Montreal, Montreal, QC H3T 1J4, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Dahoud","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology & Visual Sciences, McGill University, Montreal, QC H4A 0A4, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fares","family":"Alsaleh","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology & Visual Sciences, McGill University, Montreal, QC H4A 0A4, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9089-8683","authenticated-orcid":false,"given":"Bryan","family":"Arthurs","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology & Visual Sciences, McGill University, Montreal, QC H4A 0A4, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3601-0123","authenticated-orcid":false,"given":"Christian","family":"El-Hadad","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology & Visual Sciences, McGill University, Montreal, QC H4A 0A4, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2024,10,29]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"S2","DOI":"10.1097\/IOP.0000000000002467","article-title":"Thyroid Eye Disease: Epidemiology, Natural History, and Risk Factors","volume":"39","author":"Bartalena","year":"2023","journal-title":"Ophthal. Plast. Reconstr. Surg."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"1425","DOI":"10.1038\/s41433-024-02967-9","article-title":"The changing landscape of thyroid eye disease: Current clinical advances and future outlook","volume":"38","author":"Moledina","year":"2024","journal-title":"Eye"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"A843","DOI":"10.1210\/jendso\/bvab048.1720","article-title":"Severe thyroid eye disease in the US: A national perspective","volume":"5","author":"Singh","year":"2021","journal-title":"J. Endocr. Soc."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1007\/s40123-021-00385-8","article-title":"Quality of Life in Patients with Chronic Thyroid Eye Disease in the United States","volume":"10","author":"Cockerham","year":"2021","journal-title":"Ophthalmol. Ther."},{"key":"ref_5","doi-asserted-by":"crossref","unstructured":"Smith, T.J., Heged\u00fcs, L., Lesser, I., Perros, P., Dorris, K., Kinrade, M., Troy-Ott, P., Wuerth, L., and Nori, M. (2023). How patients experience thyroid eye disease. Front. Endocrinol., 14.","DOI":"10.3389\/fendo.2023.1283374"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"858","DOI":"10.1016\/j.survophthal.2021.08.010","article-title":"Thinking inside the box: Current insights into targeting orbital tissue remodeling and inflammation in thyroid eye disease","volume":"67","author":"Gupta","year":"2022","journal-title":"Surv. Ophthalmol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"134","DOI":"10.12688\/f1000research.12787.1","article-title":"New advances in understanding thyroid-associated ophthalmopathy and the potential role for insulin-like growth factor-I receptor","volume":"7","author":"Smith","year":"2018","journal-title":"F1000Research"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1136\/bjophthalmol-2015-307399","article-title":"Pathogenesis of thyroid eye disease: Review and update on molecular mechanisms","volume":"100","author":"Khong","year":"2016","journal-title":"Br. J. Ophthalmol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1056\/NEJMra0905750","article-title":"Graves\u2019 ophthalmopathy","volume":"362","author":"Bahn","year":"2010","journal-title":"N. Engl. J. Med."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"18856","DOI":"10.1074\/jbc.M110.179317","article-title":"Peroxisome proliferator-activated receptor \u03b3 ligands inhibit transforming growth factor-\u03b2-induced, hyaluronan-dependent, T cell adhesion to orbital fibroblasts","volume":"286","author":"Guo","year":"2011","journal-title":"J. Biol. Chem."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"340934","DOI":"10.1155\/2015\/340934","article-title":"Disturbances of Modulating Molecules (FOXP3, CTLA-4\/CD28\/B7, and CD40\/CD40L) mRNA Expressions in the Orbital Tissue from Patients with Severe Graves\u2019 Ophthalmopathy","volume":"2015","author":"Pawlowski","year":"2015","journal-title":"Mediat. Inflamm."},{"key":"ref_12","doi-asserted-by":"crossref","unstructured":"Yang, I.-H., Rose, G.E., Ezra, D.G., and Bailly, M. (2019). Macrophages promote a profibrotic phenotype in orbital fibroblasts through increased hyaluronic acid production and cell contractility. Sci. Rep., 9.","DOI":"10.1038\/s41598-019-46075-1"},{"key":"ref_13","doi-asserted-by":"crossref","unstructured":"\u0141acheta, D., Mi\u015bkiewicz, P., G\u0142uszko, A., Nowicka, G., Struga, M., Kantor, I., Po\u015blednik, K.B., Mirza, S., and Szczepa\u0144ski, M.J. (2019). Immunological Aspects of Graves\u2019 Ophthalmopathy. BioMed Res. Int., 2019.","DOI":"10.1155\/2019\/7453260"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1038\/s41433-018-0242-9","article-title":"Serial TSH-receptor antibody levels to guide the management of thyroid eye disease: The impact of smoking, immunosuppression, radio-iodine, and thyroidectomy","volume":"33","author":"Roos","year":"2019","journal-title":"Eye"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"1648","DOI":"10.1210\/jc.2013-4026","article-title":"Clinical Relevance of Thyroid-Stimulating Autoantibodies in Pediatric Graves\u2019 Disease\u2014A Multicenter Study","volume":"99","author":"Diana","year":"2014","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1210\/jc.2012-2270","article-title":"Circulating IgGs May Modulate IGF-I Receptor Stimulating Activity in a Subset of Patients with Graves\u2019 Ophthalmopathy","volume":"98","author":"Varewijck","year":"2013","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1210\/jc.2012-1771","article-title":"Autoantibodies to the IGF1 receptor in Graves\u2019 orbitopathy","volume":"98","author":"Minich","year":"2013","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"ref_18","doi-asserted-by":"crossref","unstructured":"Gontarz-Nowak, K., Szychli\u0144ska, M., Matuszewski, W., Stefanowicz-Rutkowska, M., and Bandurska-Stankiewicz, E. (2020). Current knowledge on Graves\u2019 orbitopathy. J. Clin. Med., 10.","DOI":"10.3390\/jcm10010016"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"251","DOI":"10.3109\/08916939309014643","article-title":"Autoantibodies to IGF-1 binding sites in thyroid associated ophthalmopathy","volume":"16","author":"Weightman","year":"1993","journal-title":"Autoimmunity"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"e28397","DOI":"10.1016\/j.heliyon.2024.e28397","article-title":"Comparison of orbital fibroblasts from Graves\u2019 ophthalmopathy and healthy control","volume":"10","author":"Wu","year":"2024","journal-title":"Heliyon"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"87","DOI":"10.4274\/2017.26.suppl.10","article-title":"Thyroid Stimulating Hormone Receptor","volume":"26","author":"Tuncel","year":"2017","journal-title":"Mol. Imaging Radionucl. Ther."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"4336","DOI":"10.1167\/iovs.19-27865","article-title":"TSHR Signaling Stimulates Proliferation Through PI3K\/Akt and Induction of miR-146a and miR-155 in Thyroid Eye Disease Orbital Fibroblasts","volume":"60","author":"Woeller","year":"2019","journal-title":"Investig. Ophthalmol. Vis. Sci."},{"key":"ref_23","first-page":"90","article-title":"Graves\u2019 Autoantibodies Exhibit Different Stimulating Activities in Cultures of Thyrocytes and Orbital Fibroblasts Not Reflected by Clinical Assays","volume":"32","author":"Krieger","year":"2022","journal-title":"Thyroid\u00ae"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"101245","DOI":"10.1016\/j.molmet.2021.101245","article-title":"Insulin-like growth factors: Ligands, binding proteins, and receptors","volume":"52","author":"LeRoith","year":"2021","journal-title":"Mol. Metab."},{"key":"ref_25","doi-asserted-by":"crossref","unstructured":"Hoa, N., Tsui, S., Afifiyan, N.F., Sinha Hikim, A., Li, B., Douglas, R.S., and Smith, T.J. (2012). Nuclear targeting of IGF-1 receptor in orbital fibroblasts from Graves\u2019 disease: Apparent role of ADAM17. PLoS ONE, 7.","DOI":"10.1371\/journal.pone.0034173"},{"key":"ref_26","doi-asserted-by":"crossref","unstructured":"Wang, R., Song, D., Zhong, Y., and Li, H. (2024). Potential role of IGF-1R in the interaction between orbital fibroblasts and B lymphocytes: An implication for B lymphocyte depletion in the active inflammatory phase of thyroid-associated ophthalmopathy. BMC Immunol., 25.","DOI":"10.1186\/s12865-024-00613-3"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"T29","DOI":"10.1530\/JME-17-0276","article-title":"IGF1 receptor and thyroid-associated ophthalmopathy","volume":"61","author":"Mohyi","year":"2018","journal-title":"J. Mol. Endocrinol."},{"key":"ref_28","doi-asserted-by":"crossref","unstructured":"Paik, J.S., Kim, S.-E., Kim, J.H., Lee, J.-Y., Yang, S.-W., and Lee, S.-B. (2020). Insulin-like growth factor-1 enhances the expression of functional TSH receptor in orbital fibroblasts from thyroid-associated ophthalmopathy. Immunobiology, 225.","DOI":"10.1016\/j.imbio.2019.151902"},{"key":"ref_29","doi-asserted-by":"crossref","unstructured":"Kiernan, K., Alwarawrah, Y., Nichols, A.G., Danzaki, K., and MacIver, N.J. (2024). Insulin and IGF-1 have both overlapping and distinct effects on CD4+ T cell mitochondria, metabolism, and function. Sci. Rep., 14.","DOI":"10.1038\/s41598-024-54836-w"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"4273","DOI":"10.1210\/jc.2017-01349","article-title":"Regulation of Orbital Fibrosis and Adipogenesis by Pathogenic Th17 Cells in Graves Orbitopathy","volume":"102","author":"Fang","year":"2017","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"103534","DOI":"10.1016\/j.autrev.2024.103534","article-title":"Redox mechanisms in autoimmune thyroid eye disease","volume":"23","author":"Buonfiglio","year":"2024","journal-title":"Autoimmun. Rev."},{"key":"ref_32","first-page":"83","article-title":"Current perspectives on the role of orbital fibroblasts in the pathogenesis of Graves\u2019 ophthalmopathy","volume":"142","author":"Dik","year":"2016","journal-title":"Role Ocul. Fibros. Ophthalmic Dis."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.1016\/S0006-291X(77)80113-7","article-title":"Evidence for prostaglandin production by human lymphocytes during culture with human thyroid cells in monolayer: A possible role for prostaglandins in the pathogenesis of graves\u2019 disease","volume":"77","author":"Rapoport","year":"1977","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"54","DOI":"10.3390\/stresses4010004","article-title":"Orbital Inflammation in Thyroid Eye Disease: Stress Responses and Their Implications","volume":"4","author":"Aoun","year":"2024","journal-title":"Stresses"},{"key":"ref_35","doi-asserted-by":"crossref","unstructured":"Ahsanuddin, S., and Wu, A.Y. (2023). Single-cell transcriptomics in thyroid eye disease. Taiwan J. Ophthalmol.","DOI":"10.4103\/tjo.TJO-D-23-00096"},{"key":"ref_36","first-page":"3052","article-title":"Activating the aryl hydrocarbon receptor with naturally occurring compounds to mitigate thyroid eye disease orbital fibroblast activation","volume":"65","author":"Patrick","year":"2024","journal-title":"Investig. Ophthalmol. Vis. Sci."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1210\/clinem\/dgac045","article-title":"It Takes Two to Tango: IGF-I and TSH Receptors in Thyroid Eye Disease","volume":"107","author":"Girnita","year":"2022","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1167\/iovs.65.2.25","article-title":"SOX9 Induces Orbital Fibroblast Activation in Thyroid Eye Disease Via MAPK\/ERK1\/2 Pathway","volume":"65","author":"Zhou","year":"2024","journal-title":"Investig. Ophthalmol. Vis. Sci."},{"key":"ref_39","doi-asserted-by":"crossref","unstructured":"Galgoczi, E., Orsos, I., Molnar, Z., Ujhelyi, B., Steiber, Z., Szabo, L., Dienes, B., Csernoch, L., Nagy, E.V., and Katko, M. (2024). Modelling of mechanical stimuli through piezo1 receptor activation and its effect on adipogenic differentiation of orbital fibroblasts. Endocrine Abstracts, Bioscientifica.","DOI":"10.1530\/endoabs.101.PS1-01-01"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"1465","DOI":"10.1089\/thy.2023.0309","article-title":"Yes-Associated Protein Mediates the Transition from Inflammation to Fibrosis in Graves\u2019 Orbitopathy","volume":"33","author":"Ko","year":"2023","journal-title":"Thyroid\u00ae"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1111\/cen.14296","article-title":"Prevalence of thyroid eye disease in Graves\u2019 disease: A meta-analysis and systematic review","volume":"93","author":"Chin","year":"2020","journal-title":"Clin. Endocrinol."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"12","DOI":"10.4103\/tjo.tjo_57_21","article-title":"Management of eyelid retraction related to thyroid eye disease","volume":"12","author":"Osaki","year":"2022","journal-title":"Taiwan J. Ophthalmol."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1016\/j.ecl.2021.12.004","article-title":"2022 Update on Clinical Management of Graves\u2019 Disease and Thyroid Eye Disease","volume":"51","author":"Hoang","year":"2022","journal-title":"Endocrinol. Metab. Clin. N. Am."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1038\/s41433-022-02186-0","article-title":"Changing the face of thyroid eye disease","volume":"37","author":"Ugradar","year":"2023","journal-title":"Eye"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"56","DOI":"10.4103\/ijem.ijem_280_21","article-title":"Are Severe Forms of Thyroid Eye Disease Common in the Indian Population? Clinical Characteristics of 136 Patients from a Tertiary Eye Care Centre","volume":"27","author":"Subramaniam","year":"2023","journal-title":"Indian J. Endocrinol. Metab."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.1038\/sj.eye.6702603","article-title":"Cigarette smoking and thyroid eye disease: A systematic review","volume":"21","author":"Thornton","year":"2007","journal-title":"Eye"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1097\/IOP.0000000000000371","article-title":"Recurrent Thyroid Eye Disease","volume":"31","author":"Patel","year":"2015","journal-title":"Ophthal. Plast. Reconstr. Surg."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1007\/BF03343979","article-title":"Does smoking increase relapse rates in Graves\u2019 disease?","volume":"25","author":"Kimball","year":"2002","journal-title":"J. Endocrinol. Investig."},{"key":"ref_49","doi-asserted-by":"crossref","unstructured":"Rashad, R., Pinto, R., Li, E., Sohrab, M., and Distefano, A.G. (2022). Thyroid Eye Disease. Life, 12.","DOI":"10.3390\/life12122084"},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1089\/thy.2010.1634","article-title":"Risk factors for development or deterioration of Graves\u2019 ophthalmopathy","volume":"20","author":"Stan","year":"2010","journal-title":"Thyroid"},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1210\/jc.2010-1962","article-title":"Intravenous glucocorticoids for Graves\u2019 orbitopathy: Efficacy and morbidity","volume":"96","author":"Zang","year":"2011","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"ref_52","doi-asserted-by":"crossref","unstructured":"Park, J., Kim, J., Ryu, D., and Choi, H. (2023). Factors related to steroid treatment responsiveness in thyroid eye disease patients and application of SHAP for feature analysis with XGBoost. Front. Endocrinol., 14.","DOI":"10.3389\/fendo.2023.1079628"},{"key":"ref_53","first-page":"343","article-title":"Thyroid Eye Disease","volume":"119","author":"Szelog","year":"2022","journal-title":"Mo. Med."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1097\/ICU.0000000000000529","article-title":"Thyroid eye disease: What is new to know?","volume":"29","author":"Li","year":"2018","journal-title":"Curr. Opin. Ophthalmol."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/j.jtos.2022.02.001","article-title":"Ocular Surface Disease in Thyroid Eye Disease: A Narrative Review","volume":"24","author":"Rana","year":"2022","journal-title":"Ocul. Surf."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1016\/j.jcjo.2015.05.012","article-title":"Meibomian gland dysfunction in Graves\u2019 orbitopathy","volume":"50","author":"Kim","year":"2015","journal-title":"Can. J. Ophthalmol. J. Can. Ophtalmol."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"8","DOI":"10.3109\/02713683.2010.526285","article-title":"Ocular surface and dry eye in Graves\u2019 disease","volume":"36","author":"Takmaz","year":"2011","journal-title":"Curr. Eye Res."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1111\/cen.13122","article-title":"Comparative proteomic analysis of tear fluid in Graves\u2019 disease with and without orbitopathy","volume":"85","author":"Aass","year":"2016","journal-title":"Clin. Endocrinol."},{"key":"ref_59","unstructured":"Shah, S.S., and Patel, B.C. (2024, August 02). Thyroid Eye Disease, StatPearls, Available online: http:\/\/www.ncbi.nlm.nih.gov\/books\/NBK582134\/."},{"key":"ref_60","doi-asserted-by":"crossref","unstructured":"Bajkowska, D., Szelachowska, M., Buczy\u0144ska, A., Kr\u0119towski, A.J., and Siewko, K. (2022). Tears as a Source of Biomarkers in the Diagnosis of Graves\u2019 Orbitopathy. Biomolecules, 12.","DOI":"10.3390\/biom12111620"},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"108813","DOI":"10.1016\/j.exer.2021.108813","article-title":"The Potential of Tear Proteomics for Diagnosis and Management of Orbital Inflammatory Disorders including Graves\u2019 ophthalmopathy","volume":"213","author":"Khazaei","year":"2021","journal-title":"Exp. Eye Res."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1016\/j.ajo.2008.12.007","article-title":"Occult Thyroid Eye Disease in Patients Presenting with Dry Eye Symptoms","volume":"147","author":"Gupta","year":"2009","journal-title":"Am. J. Ophthalmol."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"771","DOI":"10.3109\/02713683.2010.490320","article-title":"Topical Cyclosporine in Thyroid Orbitopathy-Related Dry Eye: Clinical Findings, Conjunctival Epithelial Apoptosis, and MMP-9 Expression","volume":"35","author":"Takmaz","year":"2010","journal-title":"Curr. Eye Res."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"3419","DOI":"10.1007\/s00417-022-05727-1","article-title":"Extraocular muscle enlargement","volume":"260","author":"Rana","year":"2022","journal-title":"Graefes Arch. Clin. Exp. Ophthalmol. Albrecht Graefes Arch. Klin. Exp. Ophthalmol."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1148\/radiology.200.1.8657923","article-title":"Optic nerve dysfunction in thyroid eye disease: A clinician\u2019s perspective","volume":"200","author":"Glatt","year":"1996","journal-title":"Radiology"},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.joco.2019.10.002","article-title":"Management of Thyroid Eye Disease-Related Strabismus","volume":"32","author":"Akbari","year":"2020","journal-title":"J. Curr. Ophthalmol."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"2335","DOI":"10.4103\/ijo.IJO_3217_21","article-title":"Update on thyroid eye disease: Regional variations in prevalence, diagnosis, and management","volume":"70","author":"Yu","year":"2022","journal-title":"Indian J. Ophthalmol."},{"key":"ref_68","unstructured":"Agarwal, A., and Khanam, S. (2024, August 02). Dysthyroid Optic Neuropathy, StatPearls, Available online: http:\/\/www.ncbi.nlm.nih.gov\/books\/NBK564299\/."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1016\/j.survophthal.2023.01.003","article-title":"Orbital and ocular perfusion in thyroid eye disease","volume":"68","author":"Goel","year":"2023","journal-title":"Surv. Ophthalmol."},{"key":"ref_70","first-page":"336","article-title":"Associations Between Thyroid Eye Disease and Glaucoma Among Those Enrolled in the National Institutes of Health All of Us Research Program","volume":"39","author":"Delavar","year":"2023","journal-title":"Ophthal. Plast. Reconstr. Surg."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1097\/IJG.0000000000000942","article-title":"Prevalence of Ocular Hypertension and Glaucoma as Well as Associated Factors in Graves\u2019 Orbitopathy","volume":"27","author":"Kim","year":"2018","journal-title":"J. Glaucoma"},{"key":"ref_72","first-page":"1360","article-title":"Glycosaminoglycans of the human trabecular meshwork in primary open-angle glaucoma","volume":"37","author":"Knepper","year":"1996","journal-title":"Investig. Ophthalmol. Vis. Sci."},{"key":"ref_73","doi-asserted-by":"crossref","unstructured":"Wu, J., Du, Y., Li, J., Fan, X., Lin, C., and Wang, N. (2021). The influence of different intraocular pressure on lamina cribrosa parameters in glaucoma and the relation clinical implication. Sci. Rep., 11.","DOI":"10.1038\/s41598-021-87844-1"},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1016\/j.eprac.2020.11.011","article-title":"Risk Factors of Thyroid Eye Disease","volume":"27","author":"Lee","year":"2021","journal-title":"Endocr. Pract."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"1201","DOI":"10.1089\/thy.2008.0098","article-title":"Influence of the TSH receptor gene on susceptibility to Graves\u2019 disease and Graves\u2019 ophthalmopathy","volume":"18","author":"Yin","year":"2008","journal-title":"Thyroid"},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1007\/s00251-013-0702-0","article-title":"PPARg2 Ala 12 variant protects against Graves\u2019 orbitopathy and modulates the course of the disease","volume":"65","author":"Daroszewski","year":"2013","journal-title":"Immunogenetics"},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1111\/j.1365-2265.2008.03343.x","article-title":"The Pro12Ala PPAR\u03b3 gene polymorphism: Possible modifier of the activity and severity of thyroid-associated orbitopathy (TAO)","volume":"70","author":"Alevizaki","year":"2009","journal-title":"Clin. Endocrinol."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1007\/s00417-012-2073-x","article-title":"Comparison between Hardy\u2013Rand\u2013Rittler 4th edition and Ishihara color plate tests for detection of dyschromatopsia in optic neuropathy","volume":"251","author":"Glovinsky","year":"2013","journal-title":"Graefes Arch. Clin. Exp. Ophthalmol."},{"key":"ref_79","first-page":"249125","article-title":"Graves\u2019 Ophthalmopathy: VISA versus EUGOGO Classification, Assessment, and Management","volume":"2015","author":"Sabater","year":"2015","journal-title":"J. Ophthalmol."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1097\/01.APO.0000617908.29733.84","article-title":"A Novel Method of CT Exophthalmometry in Patients with Thyroid Eye Disease","volume":"9","author":"Tiong","year":"2020","journal-title":"Asia-Pac. J. Ophthalmol."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1590\/S1807-59322008000300003","article-title":"Diagnostic Ability Of Barrett\u2019s Index to Detect Dysthyroid Optic Neuropathy Using Multidetector Computed Tomography","volume":"63","author":"Monteiro","year":"2008","journal-title":"Clinics"},{"key":"ref_82","unstructured":"Shah, S.S., and Khanam, S. (2024, August 02). Orbital Color Doppler Imaging, StatPearls, Available online: http:\/\/www.ncbi.nlm.nih.gov\/books\/NBK572120\/."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"97","DOI":"10.4158\/EP-2019-0363","article-title":"TSH Receptor Antibodies: Relevance & Utility","volume":"26","author":"Kahaly","year":"2020","journal-title":"Endocr. Pract."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"S13","DOI":"10.1097\/IOP.0000000000001053","article-title":"Thyroid Stimulating Hormone Receptor Antibodies in Thyroid Eye Disease\u2014Methodology and Clinical Applications","volume":"34","author":"Diana","year":"2018","journal-title":"Ophthal. Plast. Reconstr. Surg."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1007\/s40618-020-01380-9","article-title":"Thyrotropin receptor antibodies and Graves\u2019 orbitopathy","volume":"44","author":"Diana","year":"2021","journal-title":"J. Endocrinol. Investig."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1007\/s40618-015-0254-2","article-title":"Thyroid-stimulating immunoglobulins indicate the onset of dysthyroid optic neuropathy","volume":"38","author":"Ponto","year":"2015","journal-title":"J. Endocrinol. Investig."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1007\/s40618-016-0520-y","article-title":"Sensitivity of assays for TSH-receptor antibodies","volume":"39","author":"Bitcon","year":"2016","journal-title":"J. Endocrinol. Investig."},{"key":"ref_88","doi-asserted-by":"crossref","unstructured":"L\u00f3pez Ortega, J.M., Mart\u00ednez, P.S., Acevedo-Le\u00f3n, D., and Capell, N.E. (2022). Anti-TSH receptor antibodies (TRAb): Comparison of two third generation automated immunoassays broadly used in clinical laboratories and results interpretation. PLoS ONE, 17.","DOI":"10.1371\/journal.pone.0270890"},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"179","DOI":"10.3904\/kjim.2011.26.2.179","article-title":"Diagnostic value of a chimeric TSH receptor (Mc4)-based bioassay for Graves\u2019 disease","volume":"26","author":"Lee","year":"2011","journal-title":"Korean J. Intern. Med."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1186\/s12943-022-01543-7","article-title":"Liquid biopsy: A step closer to transform diagnosis, prognosis and future of cancer treatments","volume":"21","author":"Lone","year":"2022","journal-title":"Mol. Cancer"},{"key":"ref_91","first-page":"e41221","article-title":"The Role of Liquid Biopsy in the Diagnosis and Prognosis of WHO Grade 4 Astrocytoma","volume":"15","author":"Halawa","year":"2023","journal-title":"Cureus"},{"key":"ref_92","doi-asserted-by":"crossref","unstructured":"Kulbay, M., Marcotte, E., Remtulla, R., Lau, T.H., Paez-Escamilla, M., Wu, K.Y., and Burnier, M.N. (2024). Uveal Melanoma: Comprehensive Review of Its Pathophysiology, Diagnosis, Treatment, and Future Perspectives. Biomedicines, 12.","DOI":"10.3390\/biomedicines12081758"},{"key":"ref_93","first-page":"3349","article-title":"Investigating the role of circulating microRNAs as potential biomarkers for Thyroid Eye Disease","volume":"62","author":"Douglas","year":"2021","journal-title":"Investig. Ophthalmol. Vis. Sci."},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1167\/iovs.62.1.29","article-title":"MicroRNA-130a Is Elevated in Thyroid Eye Disease and Increases Lipid Accumulation in Fibroblasts Through the Suppression of AMPK","volume":"62","author":"Hammond","year":"2021","journal-title":"Investig. Ophthalmol. Vis. Sci."},{"key":"ref_95","doi-asserted-by":"crossref","unstructured":"Kim, N., Choung, H., Kim, Y.J., Woo, S.E., Yang, M.K., Khwarg, S.I., and Lee, M.J. (2023). Serum microRNA as a potential biomarker for the activity of thyroid eye disease. Sci. Rep., 13.","DOI":"10.1038\/s41598-023-27483-w"},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"111780","DOI":"10.1016\/j.mce.2022.111780","article-title":"The miR-103a-3p\/TGFBR3 axis regulates TGF-\u03b2-induced orbital fibroblast activation and fibrosis in thyroid-eye disease","volume":"559","author":"Xie","year":"2023","journal-title":"Mol. Cell. Endocrinol."},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"G43","DOI":"10.1530\/EJE-21-0479","article-title":"The 2021 European Group on Graves\u2019 orbitopathy (EUGOGO) clinical practice guidelines for the medical management of Graves\u2019 orbitopathy","volume":"185","author":"Bartalena","year":"2021","journal-title":"Eur. J. Endocrinol."},{"key":"ref_98","first-page":"3562","article-title":"Comparison of the effectiveness and tolerability of intravenous or oral glucocorticoids associated with orbital radiotherapy in the management of severe Graves\u2019 ophthalmopathy: Results of a prospective, single-blind, randomized study","volume":"86","author":"Marcocci","year":"2001","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1530\/EJE-07-0558","article-title":"Methylprednisolone pulse therapy for patients with moderately severe Graves\u2019 orbitopathy: A prospective, randomized, placebo-controlled study","volume":"158","author":"Sasim","year":"2008","journal-title":"Eur. J. Endocrinol."},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1016\/j.beem.2011.09.004","article-title":"Prevention of Graves\u2019 ophthalmopathy","volume":"26","author":"Bartalena","year":"2012","journal-title":"Best Pract. Res. Clin. Endocrinol. Metab."},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"5234","DOI":"10.1210\/jc.2005-0148","article-title":"Randomized, single blind trial of intravenous versus oral steroid monotherapy in Graves\u2019 orbitopathy","volume":"90","author":"Kahaly","year":"2005","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"2708","DOI":"10.1210\/jc.2009-0376","article-title":"Treatment modalities for Graves\u2019 ophthalmopathy: Systematic review and metaanalysis","volume":"94","author":"Robenshtok","year":"2009","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"S56","DOI":"10.1097\/IOP.0000000000001131","article-title":"Efficacy and Safety of Immunosuppressive Agents for Thyroid Eye Disease","volume":"34","author":"Strianese","year":"2018","journal-title":"Ophthal. Plast. Reconstr. Surg."},{"key":"ref_104","first-page":"8","article-title":"Azathioprine in the treatment of thyroid-associated ophthalmopathy","volume":"122","author":"Perros","year":"1990","journal-title":"Acta Endocrinol."},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1016\/S2213-8587(18)30021-4","article-title":"Combined immunosuppression and radiotherapy in thyroid eye disease (CIRTED): A multicentre, 2 \u00d7 2 factorial, double-blind, randomised controlled trial","volume":"6","author":"Rajendram","year":"2018","journal-title":"Lancet Diabetes Endocrinol."},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/S0162-3109(00)00192-2","article-title":"Mechanisms of action of cyclosporine","volume":"47","author":"Matsuda","year":"2000","journal-title":"Immunopharmacology"},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.1056\/NEJM198911163212002","article-title":"Prednisone and cyclosporine in the treatment of severe Graves\u2019 ophthalmopathy","volume":"321","author":"Prummel","year":"1989","journal-title":"N. Engl. J. Med."},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"S47","DOI":"10.1210\/clinem\/dgac252","article-title":"Future Projections in Thyroid Eye Disease","volume":"107","author":"Barbesino","year":"2022","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"2171","DOI":"10.1007\/s40618-022-01862-y","article-title":"Sirolimus as a second-line treatment for Graves\u2019 orbitopathy","volume":"45","author":"Lanzolla","year":"2022","journal-title":"J. Endocrinol. Investig."},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1097\/IOP.0000000000001279","article-title":"Methotrexate as an Adjuvant in Severe Thyroid Eye Disease: Does It Really Work as a Steroid-Sparing Agent?","volume":"35","author":"Yong","year":"2019","journal-title":"Ophthal. Plast. Reconstr. Surg."},{"key":"ref_111","first-page":"422","article-title":"Methotrexate as a Corticosteroid-Sparing Agent for Thyroid Eye Disease","volume":"6","author":"Lin","year":"2015","journal-title":"J. Clin. Exp. Ophthalmol."},{"key":"ref_112","first-page":"128903","article-title":"Methotrexate for the treatment of thyroid eye disease","volume":"2014","author":"Strianese","year":"2014","journal-title":"J. Ophthalmol."},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1001\/jamaophthalmol.2021.6284","article-title":"Proptosis and Diplopia Response with Teprotumumab and Placebo vs the Recommended Treatment Regimen with Intravenous Methylprednisolone in Moderate to Severe Thyroid Eye Disease: A Meta-analysis and Matching-Adjusted Indirect Comparison","volume":"140","author":"Douglas","year":"2022","journal-title":"JAMA Ophthalmol."},{"key":"ref_114","first-page":"204201882095833","article-title":"Glucocorticoids in Graves\u2019 orbitopathy: Mechanisms of action and clinical application","volume":"11","author":"Kahaly","year":"2020","journal-title":"Ther. Adv. Endocrinol. Metab."},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1111\/j.1742-1241.2006.01004.x","article-title":"Comparison of intravenous methylprednisolone therapy vs. oral methylprednisolone therapy in patients with Graves\u2019 ophthalmopathy: IVGC vs. OGC in Graves\u2019 ophthalmopathy","volume":"61","author":"Aktaran","year":"2006","journal-title":"Int. J. Clin. Pract."},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"6638089","DOI":"10.1155\/2023\/6638089","article-title":"The Efficacy and Safety of Teprotumumab in Thyroid Eye Disease: Evidence from Randomized Controlled Trials","volume":"2023","author":"Lin","year":"2023","journal-title":"Int. J. Clin. Pract."},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"2473974X221097097","DOI":"10.1177\/2473974X221097097","article-title":"Audiologic Demonstration of Ototoxicity from Teprotumumab Treatment in a Patient with Thyroid Eye Disease","volume":"6","author":"Najjar","year":"2022","journal-title":"OTO Open"},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"e230043","DOI":"10.1530\/ETJ-23-0043","article-title":"Teprotumumab in thyroid eye disease: Wonder drug or great divider?","volume":"12","author":"Perros","year":"2023","journal-title":"Eur. Thyroid J."},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"e220189","DOI":"10.1530\/ETJ-22-0189","article-title":"Management of thyroid eye disease: A consensus statement by the American Thyroid Association and the European Thyroid Association","volume":"11","author":"Burch","year":"2022","journal-title":"Eur. Thyroid J."},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1097\/WNO.0000000000001134","article-title":"Teprotumumab in Clinical Practice: Recommendations and Considerations from the OPTIC Trial Investigators","volume":"41","author":"Douglas","year":"2021","journal-title":"J. Neuroophthalmol."},{"key":"ref_121","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1159\/000443828","article-title":"The 2016 European Thyroid Association\/European Group on Graves\u2019 Orbitopathy Guidelines for the Management of Graves\u2019 Orbitopathy","volume":"5","author":"Bartalena","year":"2016","journal-title":"Eur. Thyroid J."},{"key":"ref_122","doi-asserted-by":"crossref","first-page":"1920","DOI":"10.1056\/NEJMoa1012985","article-title":"Selenium and the Course of Mild Graves\u2019 Orbitopathy","volume":"364","author":"Marcocci","year":"2011","journal-title":"N. Engl. J. Med."},{"key":"ref_123","unstructured":"Yvon, C., Khong, J.J., Malhotra, R., and Patel, B.C. (2024, August 02). Teprotumumab, StatPearls, Available online: http:\/\/www.ncbi.nlm.nih.gov\/books\/NBK585036\/."},{"key":"ref_124","doi-asserted-by":"crossref","first-page":"1553","DOI":"10.1038\/s41433-021-01593-z","article-title":"Teprotumumab for the treatment of chronic thyroid eye disease","volume":"36","author":"Ugradar","year":"2022","journal-title":"Eye"},{"key":"ref_125","doi-asserted-by":"crossref","first-page":"E1635","DOI":"10.1210\/jc.2014-1580","article-title":"Teprotumumab, an IGF-1R blocking monoclonal antibody inhibits TSH and IGF-1 action in fibrocytes","volume":"99","author":"Chen","year":"2014","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"ref_126","doi-asserted-by":"crossref","unstructured":"Kamboj, A., Harrison, A.R., and Mokhtarzadeh, A. (2023). Emerging therapies in the medical management of thyroid eye disease. Front. Ophthalmol., 3.","DOI":"10.3389\/fopht.2023.1295902"},{"key":"ref_127","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1016\/j.ophtha.2021.10.017","article-title":"Teprotumumab Efficacy, Safety, and Durability in Longer-Duration Thyroid Eye Disease and Re-treatment","volume":"129","author":"Douglas","year":"2022","journal-title":"Ophthalmology"},{"key":"ref_128","doi-asserted-by":"crossref","first-page":"2098","DOI":"10.1212\/WNL.0000000000202314","article-title":"Phase 1\/2 Clinical Study of VRDN-001, A Full Antagonist Antibody to the Insulin-Like Growth Factor-1 Receptor (IGF-1R), in Patients with Thyroid Eye Disease (TED) (P3-9.001)","volume":"100","author":"Moster","year":"2023","journal-title":"Neurology"},{"key":"ref_129","first-page":"3995","article-title":"VRDN-002, A Second-Generation Insulin Like Growth Factor-1 Receptor (IGF-1R) Inhibitory Antibody for Thyroid Eye Disease: Preclinical Pharmacokinetics and Clinical Promise","volume":"63","author":"Dickinson","year":"2022","journal-title":"Investig. Ophthalmol. Vis. Sci."},{"key":"ref_130","first-page":"4038","article-title":"VRDN-002, a Next-Generation Half-life Extended Antagonist Antibody to IGF-1 Receptor for Thyroid Eye Disease (TED): Safety and Pharmacokinetic\/Pharmacodynamic (PK\/PD) Results in Healthy Volunteers","volume":"64","author":"Foster","year":"2023","journal-title":"Investig. Ophthalmol. Vis. Sci."},{"key":"ref_131","first-page":"4043","article-title":"Preclinical Pharmacokinetics of VRDN-003, A Next-Generation Half-life Extended Antibody to the IGF-1 Receptor for Thyroid Eye Disease","volume":"64","author":"Dickinson","year":"2023","journal-title":"Investig. Ophthalmol. Vis. Sci."},{"key":"ref_132","first-page":"4044","article-title":"Design and Preclinical Characterization of VRDN-003, a Next-Generation, Half-life Extended Antibody to IGF-1 Receptor in Development for Thyroid Eye Disease (TED)","volume":"64","author":"Newell","year":"2023","journal-title":"Investig. Ophthalmol. Vis. Sci."},{"key":"ref_133","doi-asserted-by":"crossref","unstructured":"Gulbins, A., Horstmann, M., Daser, A., Fl\u00f6gel, U., Oeverhaus, M., Bechrakis, N.E., Banga, J.P., Keitsch, S., Wilker, B., and Krause, G. (2023). Linsitinib, an IGF-1R inhibitor, attenuates disease development and progression in a model of thyroid eye disease. Front. Endocrinol., 14.","DOI":"10.3389\/fendo.2023.1211473"},{"key":"ref_134","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1158\/1078-0432.CCR-14-0303","article-title":"A Phase I Study of Continuous Oral Dosing of OSI-906, a Dual Inhibitor of Insulin-Like Growth Factor-1 and Insulin Receptors, in Patients with Advanced Solid Tumors","volume":"21","author":"Puzanov","year":"2015","journal-title":"Clin. Cancer Res."},{"key":"ref_135","doi-asserted-by":"crossref","first-page":"75","DOI":"10.2147\/BTT.S1828","article-title":"Review of tocilizumab in the treatment of rheumatoid arthritis","volume":"2","author":"Okuda","year":"2008","journal-title":"Biol. Targets Ther."},{"key":"ref_136","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/j.ajo.2018.07.038","article-title":"Efficacy of Tocilizumab in Patients with Moderate-to-Severe Corticosteroid-Resistant Graves Orbitopathy: A Randomized Clinical Trial","volume":"195","author":"Maneiro","year":"2018","journal-title":"Am. J. Ophthalmol."},{"key":"ref_137","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/j.ando.2020.01.003","article-title":"Tocilizumab in glucocorticoid-resistant graves orbitopathy. A case series report of a mexican population","volume":"81","year":"2020","journal-title":"Ann. Endocrinol."},{"key":"ref_138","doi-asserted-by":"crossref","unstructured":"S\u00e1nchez-Bilbao, L., Mart\u00ednez-L\u00f3pez, D., Revenga, M., L\u00f3pez-V\u00e1zquez, \u00c1., Valls-Pascual, E., Atienza-Mateo, B., Valls-Espinosa, B., Maiz-Alonso, O., Blanco, A., and Torre-Salaberri, I. (2020). Anti-IL-6 Receptor Tocilizumab in Refractory Graves\u2019 Orbitopathy: National Multicenter Observational Study of 48 Patients. J. Clin. Med., 9.","DOI":"10.3390\/jcm9092816"},{"key":"ref_139","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1097\/IOP.0000000000002573","article-title":"Efficiency and Safety of Tocilizumab for the Treatment of Thyroid Eye Disease: A Systematic Review","volume":"40","author":"Duarte","year":"2024","journal-title":"Ophthal. Plast. Reconstr. Surg."},{"key":"ref_140","doi-asserted-by":"crossref","first-page":"131","DOI":"10.18773\/austprescr.2016.053","article-title":"Rituximab in autoimmune diseases","volume":"39","author":"Randall","year":"2016","journal-title":"Aust. Prescr."},{"key":"ref_141","doi-asserted-by":"crossref","first-page":"710","DOI":"10.2215\/CJN.08500815","article-title":"Anti-CD20 Antibodies for Idiopathic Nephrotic Syndrome in Children","volume":"11","author":"Ravani","year":"2016","journal-title":"Clin. J. Am. Soc. Nephrol. CJASN"},{"key":"ref_142","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1210\/jc.2014-2572","article-title":"Randomized Controlled Trial of Rituximab in Patients with Graves\u2019 Orbitopathy","volume":"100","author":"Stan","year":"2015","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"ref_143","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1210\/jc.2014-3014","article-title":"Efficacy of B-Cell Targeted Therapy with Rituximab in Patients with Active Moderate to Severe Graves\u2019 Orbitopathy: A Randomized Controlled Study","volume":"100","author":"Salvi","year":"2015","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"ref_144","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1007\/s40265-018-0872-z","article-title":"Belimumab: A Review in Systemic Lupus Erythematosus","volume":"78","author":"Blair","year":"2018","journal-title":"Drugs"},{"key":"ref_145","doi-asserted-by":"crossref","unstructured":"Lazzaroni, E., Covelli, D., Curr\u00f2, N., Campi, I., Vannucchi, G., Dazzi, D., Muller, I., Guastella, C., Dolci, A., and Arosio, M. (2020). Comparison between the efficacy of the Anti-BAFF monoclonal antibody belimumab vs methylprednisolone in active moderate-severe graves\u2019 orbitopathy: An interim analysis. Endocrine Abstracts, Bioscientifica. Available online: http:\/\/www.endocrine-abstracts.org\/ea\/0070\/ea0070yi9.htm.","DOI":"10.1530\/endoabs.70.YI9"},{"key":"ref_146","doi-asserted-by":"crossref","first-page":"5197","DOI":"10.1167\/iovs.06-0596","article-title":"Biological Effects of Thyrotropin Receptor Activation on Human Orbital Preadipocytes","volume":"47","author":"Zhang","year":"2006","journal-title":"Investig. Opthalmology Vis. Sci."},{"key":"ref_147","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1089\/thy.2018.0349","article-title":"A New Highly Thyrotropin Receptor-Selective Small-Molecule Antagonist with Potential for the Treatment of Graves\u2019 Orbitopathy","volume":"29","author":"Marcinkowski","year":"2019","journal-title":"Thyroid"},{"key":"ref_148","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1111\/bph.13693","article-title":"Inhibiting thyrotropin\/insulin-like growth factor 1 receptor crosstalk to treat Graves\u2019 ophthalmopathy: Studies in orbital fibroblasts in vitro: Inhibiting TSHR\/IGF-1R crosstalk in Graves\u2019 ophthalmopathy","volume":"174","author":"Place","year":"2017","journal-title":"Br. J. Pharmacol."},{"key":"ref_149","first-page":"e220120","article-title":"Structure of full-length TSH receptor in complex with antibody K1-70TM","volume":"70","author":"Sanders","year":"2023","journal-title":"J. Mol. Endocrinol."},{"key":"ref_150","doi-asserted-by":"crossref","first-page":"878","DOI":"10.1111\/cen.14681","article-title":"TSH receptor specific monoclonal autoantibody K1-70TM targeting of the TSH receptor in subjects with Graves\u2019 disease and Graves\u2019 orbitopathy\u2014Results from a phase I clinical trial","volume":"96","author":"Furmaniak","year":"2022","journal-title":"Clin. Endocrinol."},{"key":"ref_151","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1159\/000511538","article-title":"Targeting TSH and IGF-1 Receptors to Treat Thyroid Eye Disease","volume":"9","author":"Neumann","year":"2020","journal-title":"Eur. Thyroid J."},{"key":"ref_152","doi-asserted-by":"crossref","unstructured":"Ciepli\u0144ska, K., Niedziela, E., and Kowalska, A. (2023). Immunological Processes in the Orbit and Indications for Current and Potential Drug Targets. J. Clin. Med., 13.","DOI":"10.3390\/jcm13010072"},{"key":"ref_153","doi-asserted-by":"crossref","unstructured":"Wu, P., Lin, B., Huang, S., Meng, J., Zhang, F., Zhou, M., Hei, X., Ke, Y., Yang, H., and Huang, D. (2022). IL-11 Is Elevated and Drives the Profibrotic Phenotype Transition of Orbital Fibroblasts in Thyroid-Associated Ophthalmopathy. Front. Endocrinol., 13.","DOI":"10.3389\/fendo.2022.846106"},{"key":"ref_154","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1007\/s40120-022-00345-9","article-title":"Therapeutic Effects of Batoclimab in Chinese Patients with Generalized Myasthenia Gravis: A Double-Blinded, Randomized, Placebo-Controlled Phase II Study","volume":"11","author":"Yan","year":"2022","journal-title":"Neurol. Ther."},{"key":"ref_155","doi-asserted-by":"crossref","first-page":"A778","DOI":"10.1210\/jendso\/bvac150.1609","article-title":"ODP509 Proof-of-concept, Multicenter, Open-Label Phase 2a Study of Batoclimab in Active and Moderate-to-Severe Thyroid Eye Disease","volume":"6","author":"Janes","year":"2022","journal-title":"J. Endocr. Soc."},{"key":"ref_156","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1016\/S2213-8587(21)00238-2","article-title":"Statins for Graves\u2019 orbitopathy (STAGO): A phase 2, open-label, adaptive, single centre, randomised clinical trial","volume":"9","author":"Lanzolla","year":"2021","journal-title":"Lancet Diabetes Endocrinol."},{"key":"ref_157","doi-asserted-by":"crossref","unstructured":"Yi, C., Niu, G., Zhang, Y., Rao, J., Liu, G., Yang, W., and Fei, X. (2024). Advances in artificial intelligence in thyroid-associated ophthalmopathy. Front. Endocrinol., 15.","DOI":"10.3389\/fendo.2024.1356055"},{"key":"ref_158","doi-asserted-by":"crossref","unstructured":"Zhang, Y., Rao, J., Wu, X., Zhou, Y., Liu, G., and Zhang, H. (2023). Automatic measurement of exophthalmos based orbital CT images using deep learning. Front. Cell Dev. Biol., 11.","DOI":"10.3389\/fcell.2023.1135959"},{"key":"ref_159","doi-asserted-by":"crossref","unstructured":"Huang, X., Ju, L., Li, J., He, L., Tong, F., Liu, S., Li, P., Zhang, Y., Wang, X., and Yang, Z. (2022). An Intelligent Diagnostic System for Thyroid-Associated Ophthalmopathy Based on Facial Images. Front. Med., 9.","DOI":"10.3389\/fmed.2022.920716"},{"key":"ref_160","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1007\/s11548-020-02281-1","article-title":"Artificial intelligence CT screening model for thyroid-associated ophthalmopathy and tests under clinical conditions","volume":"16","author":"Song","year":"2021","journal-title":"Int. J. Comput. Assist. Radiol. Surg."},{"key":"ref_161","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1007\/s00417-023-06256-1","article-title":"Use of extreme gradient boosting, light gradient boosting machine, and deep neural networks to evaluate the activity stage of extraocular muscles in thyroid-associated ophthalmopathy","volume":"262","author":"Li","year":"2024","journal-title":"Graefes Arch. Clin. Exp. Ophthalmol."},{"key":"ref_162","doi-asserted-by":"crossref","unstructured":"Moon, J.H., Shin, K., Lee, G.M., Park, J., Lee, M.J., Choung, H., and Kim, N. (2022). Machine learning-assisted system using digital facial images to predict the clinical activity score in thyroid-associated orbitopathy. Sci. Rep., 12.","DOI":"10.1038\/s41598-022-25887-8"},{"key":"ref_163","doi-asserted-by":"crossref","unstructured":"Lee, J., Lee, S., Lee, W.J., Moon, N.J., and Lee, J.K. (2023). Neural network application for assessing thyroid-associated orbitopathy activity using orbital computed tomography. Sci. Rep., 13.","DOI":"10.1038\/s41598-023-40331-1"},{"key":"ref_164","doi-asserted-by":"crossref","first-page":"2479","DOI":"10.1007\/s40123-023-00754-5","article-title":"Artificial Intelligence Automation of Proptosis Measurement: An Indicator for Pediatric Orbital Abscess Surgery","volume":"12","author":"Fu","year":"2023","journal-title":"Ophthalmol. Ther."},{"key":"ref_165","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1097\/WNO.0000000000001560","article-title":"Expert Consensus on the Use of Teprotumumab for the Management of Thyroid Eye Disease Using a Modified-Delphi Approach","volume":"42","author":"Douglas","year":"2022","journal-title":"J. Neuroophthalmol."}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/25\/21\/11628\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T16:23:21Z","timestamp":1760113401000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/25\/21\/11628"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10,29]]},"references-count":165,"journal-issue":{"issue":"21","published-online":{"date-parts":[[2024,11]]}},"alternative-id":["ijms252111628"],"URL":"https:\/\/doi.org\/10.3390\/ijms252111628","relation":{},"ISSN":["1422-0067"],"issn-type":[{"value":"1422-0067","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,10,29]]}}}